CCM
DNTH icon

Cinctive Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Cinctive Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
13,452
-80,956
-86% -$7.07M 0.05% 301
2026
Q1 		$7.92M Buy
94,408
+48,502
+106% +$2.81M 0.52% 57
2025
Q4 		$1.89M Buy
+45,906
New +$1.78M 0.1% 219

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Cinctive Capital Management's DNTH Position: Q2 2026 in Review

Cinctive Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 86% in Q2 2026, selling an estimated $7.07M and leaving 13,452 shares worth $1.31M. The position accounts for 0.05% of the portfolio, ranked #301.

Cinctive Capital Management first reported a position in DNTH in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.92M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Cinctive Capital Management held 13,452 shares of Dianthus Therapeutics worth $1.31M as of Q2 2026.
  • Cinctive Capital Management sold 80,956 Dianthus Therapeutics shares in Q2 2026, an estimated $7.07M.
  • Dianthus Therapeutics made up 0.05% of Cinctive Capital Management's portfolio in Q2 2026, its #301 holding.
  • Cinctive Capital Management first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Cinctive Capital Management's Dianthus Therapeutics position peaked at $7.92M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.